OLYSIO® sales during the first quarter 2015
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that the global first quarter net sales of OLYSIO® (simeprevir) amounted to 234 MUSD, of which 98 MUSD were sales in the USA. Medivir’s royalties based on sales for the first quarter are calculated from the lowest royalty tier and currency conversion from USD to Euro is based on the YTD exchange rate.The royalty amounted to 129 MSEK (13.8 MEUR). OLYSIO® global net sales Sales in MUSDMarket Q1 -2015 Q1-2014 ChangeUS 98 291 -66%